Search results
Showing 1441 to 1455 of 1517 results for patients and public
Sodium phenylbutyrate–ursodoxicoltaurine for treating amyotrophic lateral sclerosis [ID6246]
Discontinued Reference number: GID-TA11264
Discontinued Reference number: GID-TA11026
Atezolizumab for adjuvant treatment of renal cell carcinoma with a high risk of metastasis [ID5101]
Discontinued Reference number: GID-TA11000
In development Reference number: GID-TA11093 Expected publication date: TBC
In development Reference number: GID-TA11278 Expected publication date: TBC
In development Reference number: GID-TA11607 Expected publication date: 13 January 2027
In development Reference number: GID-TA11166 Expected publication date: TBC
Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263]
In development Reference number: GID-TA11569 Expected publication date: TBC
Benralizumab for treating eosinophilic oesophagitis in people aged 12 to 65 [ID5093]
Discontinued Reference number: GID-TA10995
In development Reference number: GID-TA11074 Expected publication date: TBC
In development Reference number: GID-TA11585 Expected publication date: TBC
Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma [ID3975]
In development Reference number: GID-TA10858 Expected publication date: TBC
Autism spectrum disorder in adults: diagnosis and management (CG142)
This guideline covers diagnosing and managing suspected or confirmed autism spectrum disorder (autism, Asperger’s syndrome and atypical autism) in people aged 18 and over. It aims to improve access and engagement with interventions and services, and the experience of care, for people with autism.
Pembrolizumab for adjuvant treatment of hepatocellular carcinoma [ID3994]
In development Reference number: GID-TA10895 Expected publication date: 29 October 2026
Pemigatinib for treating myeloid or lymphoid neoplasms with a FGFR1 rearrangement [ID6172]
Discontinued Reference number: GID-TA11109